Targeted drugs for gastric adenocarcinoma include trastuzumab, apatinib mesylate and so on, and the drugs should be applied under doctor’s guidance. Gastric adenocarcinoma is a common malignant tumor of digestive system, and the occurrence of the disease is often related to poor dietary habits, gene mutation and other factors. One of the most important therapies after diagnosis is targeted therapy, which is a precise therapy against the mutated target point and has the advantage of small side effects. Among them, trastuzumab is a drug targeting the HER2 gene, which is suitable for patients who have not previously received first-line treatment for metastatic disease, or have not received second-line or higher treatment with anti-HER2 therapy. The main adverse reactions are myocardial toxicity and infusion reactions. Apatinib mesylate is indicated for third-line and above therapy in patients with advanced gastric or gastroesophageal union adenocarcinoma. The main adverse reactions of this drug are increased blood pressure and proteinuria.